Malaria in Mauritania: retrospective and prospective overview

Khadijetou Mint Lekweiry1, Mohamed Salem Ould Ahmedou Salem1, Leonardo K Basco2,3, Sébastien Briolant4, Jamaleddine Hafid5 and Ali Ould Mohamed Salem Boukhary1*

Abstract

Malaria has become a major public health problem in Mauritania since the 1990s, with an average of 181,000 cases per year and 2,233,066 persons at risk during 1995–2012. This paper provides the first publicly available overview of malaria incidence and distribution in Mauritania. Information on the burden and malaria species distribution is critical for guiding national efforts in malaria control. As the incidence of malaria changes over time, regular updates of epidemiological data are necessary.

Keywords: Malaria, Mauritania, Morbidity, Plasmodium, Anopheles

Background

The Islamic Republic of Mauritania is situated in northwest Africa between 15 and 27° N latitude and 5 and 17° W longitude. It occupies a total surface area of 1,030,700 sq km (Figure 1). The population of Mauritania is currently estimated to be 3,378,250 inhabitants [1] (Table 1). Population pyramid shows that nearly 43.7% are under 15 years old [2]. Infant mortality rate is 77.0 per 1,000 live births [2]. The Mauritanian population belongs to several ethnic groups: Moors (including ‘white Moors’ and ‘black Moors’) and black Africans (Poular, Wolof, and Soninke). However, there are no data on the demographic weight of each ethnic group. Sedentarization and rural exodus, partly related to the periods of drought in the 1970s and 1980s, are the most significant demographic phenomena that have occurred in Mauritania since the country’s independence in 1960. Whereas the proportion of urban population was 9% in 1965, it increased to 22.7, 46.7 and 60% in 1977, 2005 and 2010, respectively. Over the same period, the nomad population rapidly decreased from 65% in 1965 to 12 and 6% in 1988 and 2000, respectively [3]. Since its independence in 1960, Mauritania has experienced intense migratory movements. Outward flows started in the 1970s mainly due to severe and frequent droughts. These early flows were mainly directed towards sub-Saharan African countries, such as Senegal, Mali, Ivory Coast, and Gambia. Inward flows, coming mainly from neighbouring countries (Senegal, Mali, Guinea Conakry, and Ivory Coast), consisted of labour migration which filled the needs of the labour market. The total number of regular immigrants in 2010 was estimated to be 99,229, corresponding to 3% of the total resident population [4]. A large inward flow of refugees and asylum seekers due to civil conflicts in African countries (i.e. Liberia, Sierra Leone, Ivory Coast, and Mali) occurred in the 1990s. Currently, Mauritania hosts 93,590 refugees, including 66,400 Malian refugees, who left their country due to the most recent conflict in Mali [5]. Within the last decade, Mauritania has also evolved into an important transit country, attracting irregular migrants from sub-Saharan African countries attempting to enter into Europe through the Canary Islands, Ceuta, and Melilla. Two-thirds of the surface area of Mauritania is covered by the Sahara Desert and one-third is sub-Saharan semi-desert. It has a low annual rainfall that increases from north to south, one rainy season from June/July to September/October, depending on the year and/or region, and a dry season (‘cold dry season’ between November to March and ‘hot dry season’ from March to June). Accordingly, the country is geographically divided into three ecological areas (Figure 2): arid Saharan zone in the north, Sahelian zone in the intermediate region
and the Senegal River valley zone in the extreme south. The arid zone covers the land surface below 150 mm isohyets. It corresponds to the Saharan climate characterized by the presence of several oases that have been established for centuries, mainly in Adrar and Tagant regions. The Sahelian zone, made up of steppe and savannah grassland, is characterized by annual rainfall of 100–300 mm. In this region, the inhabitants practice animal breeding and rain-fed agriculture. The Senegal River Valley region, sometimes known as Shemama, is a

Table 1 Population demographic data of Mauritania

| Indicator                          | Value | Reference |
|------------------------------------|-------|-----------|
| Population density (inhabitant/sq km) | 3.4   | [1]       |
| Urban population (%)               | 60    | [2]       |
| Gender                             |       |           |
| Male (%)                           | 50.2  | [2]       |
| Female (%)                         | 49.6  | [2]       |
| Age groups (%)                     |       |           |
| <15 years                          | 43.7  | [2]       |
| 15-65 years                        | 51.0  | [2]       |
| >65 years                          | 5.3   | [2]       |
| Birth rate (%)                     | 4.6   | [2]       |
| Mortality rate (%)                 | 1.3   | [2]       |
| Infant mortality (%)               | 7.7   | [2]       |
| Growth rate                        | 2.4   | [2]       |
| Life expectancy at birth (years)   | 57.5  | [2]       |
narrow belt of land that extends north and east of the Senegal River. Rainfall is higher than in other regions, ranging from 300–500 mm annually. This rainfall, combined with annual flooding of the river, provides the basis for agriculture with a potential farmland estimated at 135,000 hectares. The main and most important permanent water source in Mauritania is the Senegal River that runs along the southwestern common border with Senegal.

Malaria distribution and causative agents
The history of documented malaria cases in Mauritania is relatively recent. The official statistics, mostly based on clinical diagnosis without laboratory confirmation, show an increase of malaria cases during the last two decades from 26,933 in 1990 to 165,834 in 2012 [6] with an average of 181,000 cases per year (Figure 3). The disease is currently the leading cause of morbidity and mortality and the first cause of consultation and hospitalization in eight of 13 regions of the country. Indeed, during the transmission season (August-November), 60% of hospital admissions are due to presumptive diagnosis of malaria, which represents, on average, 25% of morbidity and over 39% of mortality at health facilities [7]. Moreover, malaria is considered the third motive of outpatient consultations at national level, after acute respiratory infections and diarrhoea [7].

Studies conducted in different regions reported the presence of four malaria species in Mauritania (Figure 4), namely Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae [8-12]. Plasmodium falciparum was the dominant species, diagnosed in 90% of reported clinical malaria cases. The recorded infection rates were variable depending on the season, region and rainfall. In the first published report from the southern region of Gorgol, Sautet et al. [8] reported 180 positive malaria cases among 307 febrile patients, corresponding to a malaria prevalence rate of 59%. Plasmodium falciparum was detected in 133 (43.3%) of 307 examined slides, followed by P. malariae with (10.7%) and P. vivax (4.5%). In another study conducted in southern Mauritania, Escudie and Hamon [13] reported two human malaria species with a predominance of P. falciparum over P. malariae. Three years later, a survey conducted in the cities of Atar in northern Mauritania and Kaedi, Kiffa, Kankoussa, Aioun, and Tamchakett in southern Mauritania, noted the presence of only P. falciparum and P. malariae, with an infection rate of 7% [10]. The sero-prevalence of malaria was also studied in schoolchildren throughout the country. It revealed a sero-prevalence of 8%, indicating a recent
history of infection with *P. falciparum* in Ksar Torchane (Saharan part of the country), 58% in Boutilimit (Sahelian region), and 34-45% in the Sahelian region of Assaba region. The survey also reported a malaria serological prevalence of 12% in March 1973 (during the dry season) and 14% in November 1972 (just after the rainy season) among schoolchildren in Nouadhhibou, a coastal city in northwestern Mauritania [14]. In a survey conducted in 1984, one year following the construction of Foum Legleita Dam in the Gorgol region, Baudon *et al.* [15] reported a very low level of anti-malarial antibodies using indirect immunofluorescence. Of the surveyed population, 73% had anti-malarial antibody titres of less than 1/40 and only 4% of them displayed antibodies titres of 1/640 or above.

More recently, studies conducted in Nouakchott, the capital city of Mauritania, showed that infection due to malaria has increased with a high rate of infection due to *P. vivax*. In 2003, Cortes *et al.* [11] found 77 positive slides out of 446 blood smears collected from febrile patients attending health facilities in Nouakchott. Malaria infection rate was 18.5% (77/446), with 61.8% due to *P. falciparum* and 35.5% due to *P. vivax*. The authors also found nine malaria cases (seven due to *P. falciparum* and two due to *P. vivax*), which were considered as autochthonous. Moreover, Mint Lekweiry *et al.* [12] reported a malaria prevalence of 25.7% (61/237) among febrile patients attending three health facilities in Nouakchott in 2007. The majority of these cases were due to *P. vivax* (43/61, 70.5%), followed by *P. ovale* (15/61, 24.6%) and *P. falciparum* (3/61, 4.9%) by microscopy. PCR performed on these samples confirmed all *P. vivax* and *P. falciparum* infections, but cases initially diagnosed to be *P. ovale* infections by microscopy turned out to be *P. vivax* by PCR. Therefore, after PCR correction, the proportion of *P. vivax* to *P. falciparum* was 58/61 (95.1%), and no *P. ovale* or *P. malariae* malaria parasites were detected by PCR. This study also revealed that among 237 recruited febrile patients, 231 were clinically diagnosed and treated as malaria cases and that false positive constituted 73.6% of the clinically diagnosed malaria. This finding highlights the importance of the timely use of microscopy and, in case of unavailability of microscopes and/or well-trained microscopists, an alternative reliable laboratory tool, in particular rapid diagnostic tests for malaria, will play a major role in establishing the correct diagnosis and appropriate treatment.

In the follow-up study performed in 2009–2010, the same authors found a malaria prevalence of 34.9% (105 of 301 febrile patients) among children born and residing permanently in Nouakchott [16]. Among these patients with malaria confirmed by microscopy, rapid diagnostic test and PCR, 102 of 105 (97.1%) infections were due to *P. vivax* and 2.9% (three of 105) were caused by *P. falciparum*. The results of this 2009–2010 study confirmed malaria prevalence among febrile patients and distribution of *Plasmodium* spp. in Nouakchott. Moreover, 54 of the *P. vivax*-infected children had never travelled outside Nouakchott, suggesting that malaria transmission occurs within the city and that *P. vivax* is the principal causative agent.

In general, while malaria diagnosis, based on thick and thin smears, previously reported the presence of four malaria species in the country [8–11], more recent data obtained using nested PCR showed the presence of only *P. vivax* and *P. falciparum* in Nouakchott and southern Mauritania [12,16,17]. Furthermore, malaria affects all age groups in the country [7,11]. However, data on morbidity and mortality associated with this disease are underestimated due to limited health information and insufficient resources to confirm diagnosis with microscopy (or rapid diagnostic test for malaria) in most health centres. Most febrile patients tend to practice self-medication for fever at home or prefer consulting private health sectors, for which there are no health data in the country. It is worth noting that despite the publication of several papers demonstrating *P. vivax* endemicity in Nouakchott, the World Malaria Report 2013 erroneously indicates that Mauritania is free of *P. vivax*, demonstrating a gap in the quality of national data submitted to WHO [6].

**Population structure and drug resistance of malaria parasites**

In 1991, during the survey of anti-malarial drug resistance in West Africa, Guiuqemde *et al.* [18] reported that only Mauritania is still spared from chloroquine resistance. Three years later, chloroquine-resistant *P. falciparum* was detected in the autochthonous Mauritanian population. Gasquet *et al.* [19] investigated clinical response to chloroquine among 37 febrile patients infected with *P. falciparum* attending the health facility in Kiffa (Assaba region) with the following characteristics: a minimum parasite density of 1,000 asexual parasites/μl of blood, absence of chloroquine in the urine, and no recent history of treatment with other anti-malarial agents. The patients received a standard dose of 25 mg base of chloroquine per kg body weight over three days and were followed until day 7. Six patients were lost to follow-up. Three (9.7%) of the 31 enrolled patients had recurrent asexual parasitaemia, and one patient remained febrile on day 7, suggesting clinical resistance to chloroquine.

Jelinek *et al.* [20] combined a clinical study on chloroquine efficacy, conducted in 1998, with an analysis of molecular markers for drug resistance, *P. falciparum* chloroquine resistance transporter (*pfCRT*) and *P. falciparum* multidrug-resistance gene 1 (*pfdmrd1*), after an unusually
heavy rainfall in Aioun and Kobeni, southern Mauritania. Clinical chloroquine resistance was detected in 33 of 85 (38.8%; 19 (22.3%) R1 resistance and 14 (16.5%) RII/RIII resistance) *P. falciparum*-infected patients followed until day 14. Molecular analysis showed a sensitivity for detection of clinical resistance of 60.6% and a specificity of 65.3% for *pfmdr1* 76-tyrosine mutant allele while Lys76Thr mutation in *pfert* gene showed a very high sensitivity (100%) but low specificity (65.4%) to detect clinical resistance. The combination of mutations in both genes decreased the sensitivity to 60.6% while specificity increased to 76.9%. The authors concluded that *pfert*, but not *pfmdr1*, may be useful to monitor chloroquine resistance in Mauritania.

Molecular analysis of resistance to antifolates (pyrimethamine and sulphadoxine) was performed by Eberl et al. [21] using the same blood samples collected in Aioun and Kobeni in an earlier study [20]. These authors examined 162 *P. falciparum* isolates collected in Hodh Elgharbi region (southeast Mauritania) from patients recruited at two medical centres in Aioun, the regional capital city and Kobeni, a small city near the border with Mali, for point mutations in dihyrofolate reductase (*dhfr*) (codons 16, 51, 59, 108, and 164) and dihydropteroate synthase (*dhps*) genes (codons 436, 437, 540, 581 and 613). *Dhfr* mutations were found at a low prevalence both in Aioun and Kobeni (18.6% of samples from Aioun and 12.6% of samples from Kobeni showed at least one mutation), whereas a high prevalence of *dhps* mutations was noted among isolates from Aioun (74.6%) and Kobeni (63.4%), respectively. These results suggested that sulphadoxine-pyrimethamine may be effective for intermittent preventive treatment in pregnant Mauritanian women (the only current indication of sulphadoxine-pyrimethamine in Mauritania), but more clinical information is required to confirm the molecular findings.

In 2012, Mint Lekweiry et al. [22] reported a low prevalence of mutants in the *P. vivax* population isolated from 110 malaria-infected patients in Nouakchott. Indeed, the majority of the isolates (n = 100, 90.9%) were genotyped as wild-type *P. vivax dhfr* (*pvdhfr*), while the remaining ten isolates carried the Ser58Arg and Ser117Asn double mutations (homologues of Cys59Arg and Ser108Asn in *P. falciparum dhfr*). All isolates had the wild-type *P. vivax dhps* (*pvdhps*) alleles. For *P. vivax* multidrug resistance gene 1 (*pvmnd1*), 75 of 103 (73%) had the wild-type Tyr976, and 28 (27%) carried the mutant Phe976. Most (98%) carried the mutant Leu1076 codon. Of 105 isolates, 102 (97%) had one gene copy and three (3%) had two copies of the *pvmnd1* gene. *Pvmnd1* mutations have been suggested to be associated with chloroquine resistance in *P. vivax*, whereas an increased number of copy number has been associated with resistance to mefloquine [23,24].

Studies on the genetic structure of *Plasmodium* spp. populations in Mauritania are very limited. Jordan et al. [17] genotyped 173 *P. falciparum* isolates, collected in Aioun and Kobeni in 1998 as part of the clinical study on chloroquine efficacy, for three polymorphic genetic markers: merozoite surface protein 1 (*msp1*) and merozoite surface protein 2 (*msp2*), and glutamate-rich protein (*glurp*). The differences in the population structure between the two study areas were seen in both the mean number of distinct parasite populations per infection (1.57 for Aioun and 2.34 for Kobeni) and their distribution in different allelic groups. For *msp2*, the differences in the number of size variations and amplified fragments were observed in the *msp2* FC27 allelic family. Isolates from Aioun showed one or two bands with six different sizes, while amplification of the samples from Kobeni produced up to four bands with 18 different band sizes. However, analysis of *glurp* provided no further conclusive information because all samples showed a single band of the same size, suggesting limited heterogeneity of *P. falciparum* populations circulating in this region. More recently, Ould Ahmedou Salem et al. [25] examined and compared the genetic diversity of *msp1* block 2 region among *P. falciparum* isolates in Nouakchott, the capital city of Mauritania, and Hodh Elgharbi region (southeast of Mauritania). K1, Mad20 and R033 *msp1* alleles were identified with 27 different sized alleles. Infection with multiple *P. falciparum* populations was observed in the two regions (93/113; 82.3%), as well as a high multiplicity of infection (3.2 genotypes per infection), reflecting both the high endemicity level and malaria transmission in the study areas.

**Malaria vectors**

The first published studies on malaria vectors date back to the 1940s [8], followed by those of Maffi [26] and Hamon et al. [27]. These authors reported the presence of the following 12 *Anopheles* species and subspecies in Mauritania: *Anopheles funestus*, *Anopheles gambiae* s.l., *Anopheles pharoensis*, *Anopheles rufipes*, *Anopheles melas*, *Anopheles dлитali*, *Anopheles rhodesiensis*, *Anopheles coustani*, *Anopheles ziemanni*, *Anopheles pretoriensis*, *Anopheles squamosus*, and *Anopheles demilloni*. Among these anopheline species, only *An. gambiae* and *An. funestus* are known to be major malaria vectors in Africa. In Mauritania, *An. gambiae* s.l. appears to be the dominant malaria vector [8,28]. However, until today, their distribution in the country has not been established (Table 2).

Recently, Dia et al. [28] studied the distribution, host preference and infection rates of three malaria vectors, *Anopheles arabiensis*, *An. pharoensis* and *An. funestus*, in 21 localities in five regions in Mauritania, namely Trarza, Brakna, Assaba, Hodh Elgharbi and Tagant. They collected...
Table 2 Distribution of the *Anopheles gambiae* complex and *Anopheles funestus* group in Mauritania

| Region         | Anopheles sp.                                      | Reference |
|----------------|---------------------------------------------------|-----------|
| Adrar          | No data                                           |           |
| Assaba         | *An. arabiensis*; *An. gambiae*; *An. gambiae* s.l. and *An. funestus* | [26-28]   |
| Brakna         | *An. gambiae*; *An. gambiae* s.l. and *An. funestus* | [8,29]    |
| Gorgol         | *An. gambiae* s.l. and *An. funestus*              | [8]       |
| Guidimaka      | *An. gambiae* s.l.                                | [27]      |
| Hodh Echargui  | *An. gambiae* s.l.                                | [27]      |
| Hodh Elgarbi   | *An. gambiae*                                     | [28]      |
| Inchiri        | No data                                           |           |
| Nouadhibou     | No data                                           |           |
| Nouakchott     | *An. arabiensis*; *An. gambiae* s.l.              | [29,12,30]|
| Tagant         | *An. gambiae* s.l.                                | [28]      |
| Trazza         | *An. gambiae* s.l. and *An. funestus*             | [28]      |
| Tirs zemmour   | No data                                           |           |

647 anopheline specimens, among which *An. gambiae* s.l. was the most commonly identified species (92%), followed by *An. pharoensis* (5%) and *An. funestus* (3%). *Anopheles gambiae* was collected in all localities except in Moudjera (north of the country) where there was no mosquito captured during the study period. The molecular identification of the *An. gambiae* complex revealed the predominance of *An. arabiensis* and the presence of *An. gambiae* (M form) in Assaba, Brakna and Hodh Elgarbi regions. In Nouakchott, the presence of anopheline mosquitoes (*An. gambiae* s.l.) was first reported in Toujounin district [29]. More recently, Mint Lekweiry et al. [12] demonstrated the presence of *An. arabiensis* and *An. pharoensis* in Dar Naim district in Nouakchott. Ould Ahmedou Salem et al. [30] have recently shown, for the first time, the existence of *An. gambiae* s.l. larval habitats in Nouakchott and described their ecological and physico-chemical characteristics. They reported that water bodies consisting of water discharged from standpipes and household drinking water tanks served as *Anopheles* spp. larval habitats. Using multivariate regression analyses, it was further shown that salinity up to 0.1 g/l and shaded habitats were protective factors against high larval density in breeding sites and that pH up to 7.61 was a risk factor to develop high larval density in these breeding sites. However, studies on bionomics, epidemiology of anopheline species, and their involvement in malaria transmission remain poorly understood although the presence of *P. falciparum* and *P. vivax* sporozoites was demonstrated in the salivary glands of *An. arabiensis* collected in Mauritania [28,31].

National malaria control programme: policy strategy and plans

The Mauritanian Ministry of Health executes malaria control through the National Malaria Control Programme, which has elaborated a quadrennial strategic plan against malaria epidemics and endemicity. The stated goal of the latest plan for 2011–2015 is to reduce, by 2015, malaria-related morbidity and mortality from 17.5% and 0.39 per 100,000 inhabitants in 2011 to 10.9% and 0.15 per 100,000 inhabitants in 2015, respectively [2]. The strategies for achieving this goal are based on the establishment of a monitoring system, early detection of malaria epidemics, reliable laboratory-based diagnosis and appropriate and effective treatment of malaria cases, a system of prevention of and appropriate response to malaria epidemics, and collection of factual evidence on malaria epidemics. The promotion and distribution of insecticide-treated bed nets (ITNs) among populations living in endemic areas, particularly during the transmission season, the use of sulphasoxine-pyrimethamine for intermittent preventive treatment (IPT) to control malaria during pregnancy, particularly during the first and second pregnancies, are the main objectives of this strategy.

As of 2014, ITNs have been distributed free of charge to the major risk groups in southern Mauritania, i.e. among pregnant women, and IPT has been effectively implemented since 2008 [32]. However, intradomiciliary residual spraying and larval control have not been recommended by the Mauritanian National Malaria Control Programme. Laboratory diagnosis of malaria is free of charge for febrile patients of all ages in the public sector and is mainly based on the use of rapid diagnostic test, and not microscopy, due to the shortage of microscopes under working condition and well-trained microscopists. In addition, it is recommended for travellers visiting endemic areas in the south to use chemoprophylaxis (atovaquone-proguanil, doxycycline or mefloquine) starting from ten to 21 days before departure, during their stay and three weeks following their return from these regions [33]. Furthermore, a national malaria day has been organized annually since 1996 by the Ministry of Health to inform and educate the public about the importance and risks of malaria.

It is worth noting that in 2006, following the emergence of chloroquine-resistant *P. falciparum* in West Africa, particularly in the Senegal River Basin, the Mauritanian Government decided to replace chloroquine with artemisinin-based combination therapy (ACT). This policy change was principally based on clinical studies conducted in Senegal and extrapolated to the Mauritanian situation. Regardless of the parasite species involved, the treatment of uncomplicated malaria is currently based on artesunate-amodiaquine as the first-line treatment, artemether-lumefantrine as the second choice, and quinine as the
third-line drug [7]. Monotherapies using artemisinin derivatives have been withdrawn, and ACT is provided free of charge to laboratory-confirmed malaria-infected patients of all ages in the public sector. For the treatment of P. vivax malaria, the National Malaria Control Programme recommends the use of primaquine for radical treatment if glucose-6-phosphate dehydrogenase (G6PD) test is normal. This drug policy has not yet been implemented in the field. As part of future prospective studies aiming to develop an evidence-based national anti-malarial drug policy, the National Malaria Control Programme and the University of Sciences, Technology and Medicine in Nouakchott have been collaborating since 2012 to conduct clinical studies in several sentinel sites in the country to validate and, if needed, modify the current anti-malarial treatment guidelines.

Conclusion
Mauritania faces several challenges in the management of malaria, including limited financial resources, crisis in human resources, shortage of health workers and health structures with reliable diagnostic facilities, insufficient epidemiological data on parasite distribution and malaria vectors, and regular epidemics. Entomological studies are currently being conducted at several sentinel sites in different epidemiological strata in the country to capture and collect mosquito larvae and adults, identify predominant Anopheles spp. in each study site, characterize physico-chemical factors in the breeding sites, determine whether adult female Anopheles mosquitoes are infective, and assess their sensitivity to insecticides. In parallel, malaria burden and drug resistance are being assessed in these sentinel sites to determine the prevalence of laboratory-confirmed malaria among febrile patients and their response to ACT. Research capacity building and training of laboratory technicians and general practitioners are integral parts of these on-going field activities. The introduction of ACT is another challenge facing Mauritania. One of the key issues is the cost of ACT, which is 20 times higher than the cost of conventional therapy, such as quinine ($2.44 per adult dose). Population migration from sub-Saharan endemic countries constitutes another challenge where no official measures for controlling malaria prevalence among these migrants exist. Mauritania still does not have a reliable database on malaria epidemiology. A nationwide malaria indicator survey is being planned to fill this gap in 2015. Updated information and maps on malaria burden and Plasmodium species distribution are critical for guiding national efforts to improve laboratory diagnosis, implement rapid and effective treatment, and coordinate and plan malaria elimination from the country in the near future. As malaria incidence changes over time, regular updates of epidemiological data are necessary.

Abbreviations
PCR: Polymerase chain reaction; PFCRT: Plasmodium falciparum chloroquine resistance transporter; PFMDR1: Plasmodium falciparum multidrug-resistance gene 1; Lys: Lysine; Thr: Threonine; DHFR: Dihydrofolate reductase; DHPS: Dihydropteroate synthase; Asn: Asparagine; Arg: Arginine; Leu: Leucine; MSP1: Merozoite surface protein 1; MSP2: Merozoite surface protein 2; GLURP: Glutamate-rich protein; PVDHRP: Plasmodium vivax dihydrofolate reductase; Ser: Serine; Cys: Cysteine; PFDHC: Plasmodium vivax dihydropteroate synthase; PVMDR1: Plasmodium vivax multidrug resistance gene 1; Tyr: Tyrosine; Phe: Phenylalanine; ITN: Insecticide-treated bed nets; IPT: Intermittent preventive treatment; ACT: Artemisinin-based combination therapy.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KML and MSOAS drafted the manuscript. AOMSB, LKB, SB, and JEH conceived and revised the draft. All authors read and approved the final manuscript.

Acknowledgements
We thank the 5% Initiative and also Expertise France (previously France Expertise Internationale) for supporting this work through the 12INP215 grant. We also thank all staff of the library of the French Army Institute of Biomedical Research (IRBA) for their help.

Author details
1 UR Génome et Milieux, Faculté des Sciences et Techniques, Université des Sciences, de Technologie et de Médecine, Nouveau Campus Universitaire, BP 5026 Nouakchott, Mauritania. 2 Unité de Parasitologie, Institut de Recherche Biomédicale des Armées, ancienne base aérienne 217, B. P. 73, 91223 Brétigny-sur-Orge, France. 3 Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Unité de Recherche 198-Institut de Recherche pour le Développement, Faculté de Médecine La Timone, Aix-Marseille Université, 27 boulevard Jean Moulin, 13385 Marseille, France. 4 Institut de Recherche Biomédicale des Armées, Direction interarmées du service de Santé, Laboratoire de Parasitologie, CNRS du Paludisme région Antilles-Guyane, Institut Pasteur de la Guyane, Cayenne, Cedex, France. 5 Laboratoire Aliments, Environnement et Santé (LAES), Faculté des Sciences et Techniques, Université Cadi Ayyad, Marrakech, Morocco.

Received: 18 August 2014 Accepted: 8 February 2015
Published online: 04 March 2015

References
1. Office National de Statistique. Annuaire statistique 2012. Mauritanie: Ministère des affaires économiques et du développement, 2013. p. 108.
2. Ministère de la Santé. Plan National de Développement Sanitaire. (2012–2020), Mauritania 2011, p. 135.
3. Cheikh Malainine ML. Recension périodique de la population et de l’habitat 2000 en Mauritanie: particularité du milieu nomade. New York: United Nations Statistics division, Global Review of 2000 Round of Population and Housing Censuses: Mid-decade Assessment and Future Prospects; 2001. p. 7–10.
4. United Nations. Trends in International Migrant Stock: The 2008 Revision (United Nations database, POP/DB/MIG/Stock/Rev.2008). (http://esa.un.org/migration/index.asp?panel=2), 2009.
5. UNHCR. UNHCR Global Report 2013, Mauritania. (http://www.unhcr.org/53980f6b6.html).
6. WHO. World malaria report 2013. Geneva: World Health Organization; 2013.
7. Ministère de la Santé. Programme national de lutte contre le paludisme: politique et stratégies nationales de lutte contre le paludisme (2011–2015). Mauritania 2011.
8. Sautet J, Ranque J, Vuillet F, Vuillet J. Quelques notes parasitologiques sur le paludisme et l’anophélisme en Mauritanie. Med Trop (Mars). 1948;8:32–9.
9. Hudleston J. Programme de préradication du paludisme, Kaédi, Mauritanie 1961. WHO/AFR/MAL/74, 1961, p. 17.
10. Barbé Y, Timbila R. Notes sur le paludisme en République Islamique de Mauritanie. Med Trop (Mars). 1964;24:427–36.
11. Cortes H, Morillas-Marquez F, Valero A. Malaria in Mauritania: the first cases of malaria endemic to Nouakchott. Trop Med Int Health. 2003;8:297–300.
12. Mint Lekweiry K, Ould Abdallahi M, Ba H, Amathau C, Durand P, Trappe JF, et al. A preliminary study of malaria incidence in Nouakchott, Mauritania. Malar J. 2009;8:92.
13. Escudie A, Hamon J. Le paludisme en Afrique Occidentale d’expression française. Med Trop (Mars). 1961;1:261–37.
14. Monjou L, Richard-Lenoble D, Palmetier R, Daniel Ribeiro C, Alfred C, Gentilini M. A sero-epidemiological survey of malaria in desert and semi-desert regions of Mauritania. Ann Trop Med Parasitol. 1984;78:71–3.
15. Baudon D, Robert V, Darnet F, Huere M. Impact de la construction d’un barrage avec retenue d’eau sur la transmission du paludisme (enquête paludologique menée dans le Sud-Est de la Mauritanie). Bull Soc Path Exot. 1986;79:123–9.
16. Mint Lekweiry K, Basco LK, O Ahmedou Salem MS, Hafid JE, Marin-Jaufre A, O Weddih A, et al. Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg. 2011;105:727–33.
17. Jordan S, Jelinek T, Aida AO, Peyerl-Hoffmann G, Heuschkel C, El Valy AO, et al. Population structure of Plasmodium falciparum isolates during an epidemic in southern Mauritania. Trop Med Int Health. 2001;6:761–6.
18. Guiguemde TR, Gbary AR, Ouedraogo JB, Gayibor A, Lamizana L, Maiga AS, et al. Point actuel sur la chimiorésistance du paludisme des sujets autochtones dans les Etats de l’OCCGE (Afrique de l’Ouest). Ann Soc Belg Med Trop. 1991;71:199–207.
19. Gasquet M, Delmont J, Le Bras J, Delmas F, Capdegelle P, Timon-David P. Chloroquine-resistant falciparum malaria in Mauritania. Lancet. 1995;346:1556.
20. Jelinek T, Aida AO, Peyerl-Hoffmann G, Jordan S, Mayor A, Heuschkel C, et al. Diagnostic value of molecular markers in chloroquine resistant falciparum malaria in southern Mauritania. Am J Trop Med Hyg. 2002;67:449–53.
21. Eberl KJ, Jelinek T, Aida AO, Peyerl-Hoffmann G, Heuschkel C, El Valy AO, et al. Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania. Trop Med Int Health. 2001;6:756–60.
22. Mint Lekweiry K, Ould Mohamed Salem Boukhary A, Gaillard T, Wurtz N, Bogreau H, Hafid JE, et al. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother. 2012;67:367–74.
23. Brega S, Melein B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al. Identification of the Plasmodium vivax mdr-1 gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemity. J Infect Dis. 2005;191:272–7.
24. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis. 2008;198:1558–64.
25. Ould Ahmedou Salem MS, Ndiaye M, OuldAbdallahi M, M Lekweiry K, Bogreau H, Konaté L, et al. Polymorphism of the merozoite surface protein-1 block 2 region in Plasmodium falciparum isolates from Mauritania. Malar J. 2014;13:26.
26. Maffi M. Contribution à la connaissance de la faune anophéline de la Mauritanie. WHO/Ma/434. World Health Organization, Geneva, 1964. (http://www.who.int/iris/handle/10665/65168).
27. Hamon J, Maffi M, Grenier P, Ouedraogo CS, Djime D. Notes sur les moustiques de la République Islamique de Mauritanie (Diptera: Culicidae) (2e partie). Ann Soc Entomol Fr. 1966;2:371–83.
28. Dia I, Ba H, Ould Mohamed SA, Diallo D, Lo B, Diallo M. Distribution, host preference and infection rates of malaria vectors in Mauritania. Parasite Vectors. 2009;2:61.
29. Coulibaly A. Analyse du système vectoriel du district de Nouakchott. OMS Mauritanie. Programme National de Lutte contre le Paludisme; 1997.
30. Ould Ahmedou Salem MS, Mint Lekweiry K, Mint Hasni M, Konate L, Briolant S, Faye O, et al. Characterization of anopheline (Diptera: Culicidae) larval habitats in Nouakchott, Mauritania. J Vector Borne Dis. 2013;50:302–6.
31. Mint Lekweiry K, Basco LK, Ould Ahmedou Salem MS, Hafid JE, Marin-Jaufre A, Bouchiba H, et al. Malaria prevalence, morbidity and drug resistance in Nouakchott, Trop Med Int Health. 2011;16 Suppl 1:136–7.
32. WHO. World malaria report 2014. Geneva: World Health Organization; 2014.
33. Anonymous. Health recommendations for travellers (for health professionals). Bull Epidémiol Hebd. 2013;22–23:240–65.